U.S. Markets closed

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1700+0.0600 (+1.93%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1100
Open3.2899
Bid2.8700 x 1200
Ask3.4100 x 1300
Day's Range3.1700 - 3.2700
52 Week Range2.7700 - 4.1800
Volume18,923
Avg. Volume69,556
Market Cap47.299M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.2200
Earnings DateMay 18, 2021 - May 24, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates
    Zacks

    Cumberland Pharmaceuticals (CPIX) Beats Q4 Earnings and Revenue Estimates

    Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 4.93%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Recap: Cumberland Q4 Earnings

    Shares of Cumberland (NASDAQ:CPIX) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 88.89% over the past year to $0.01, which beat the estimate of ($0.01). Revenue of $10,262,000 declined by 24.97% year over year, which beat the estimate of $9,780,000. Outlook Cumberland hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 09, 2021 View more earnings on CPIX Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/3x85aqjk Price Action 52-week high: $4.30 52-week low: $2.77 Price action over last quarter: Up 12.93% Company Profile Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 9, 2021Cumberland Earnings Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020
    PR Newswire

    Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the fourth quarter were $10.3 million, up 10% over the prior year period. For the full year 2020, Net Revenues totaled $37.4 million, a 9% increase over 2019. The company also recorded an additional $3.2 million in revenue during the year associated with divested product rights for two brands it is no longer distributing.